Enliven Therapeutics (NASDAQ:ELVN) Trading Down 8% – Here’s What Happened

Enliven Therapeutics, Inc. (NASDAQ:ELVN)’s share price was down 8% during trading on Monday . The company traded as low as $24.50 and last traded at $23.9150. Approximately 71,215 shares were traded during trading, a decline of 97% from the average daily volume of 2,503,471 shares. The stock had previously closed at $26.00.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on ELVN shares. Weiss Ratings restated a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Wednesday, October 8th. Wall Street Zen upgraded shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Enliven Therapeutics has an average rating of “Moderate Buy” and an average price target of $41.00.

Enliven Therapeutics Stock Down 3.7%

The stock has a market cap of $1.49 billion, a price-to-earnings ratio of -13.60 and a beta of 0.41. The business’s 50 day simple moving average is $19.07 and its 200 day simple moving average is $19.95.

Enliven Therapeutics (NASDAQ:ELVN) last issued its earnings results on Thursday, November 13th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.11. Equities research analysts forecast that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Insider Buying and Selling at Enliven Therapeutics

In other news, COO Anish Patel sold 6,667 shares of the stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $17.40, for a total transaction of $116,005.80. Following the transaction, the chief operating officer owned 269,974 shares in the company, valued at approximately $4,697,547.60. This trade represents a 2.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Joseph P. Lyssikatos sold 12,500 shares of Enliven Therapeutics stock in a transaction that occurred on Monday, October 20th. The stock was sold at an average price of $22.08, for a total value of $276,000.00. Following the sale, the insider directly owned 915,188 shares of the company’s stock, valued at approximately $20,207,351.04. The trade was a 1.35% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 68,330 shares of company stock worth $1,434,762 over the last ninety days. Insiders own 25.90% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Invesco Ltd. increased its stake in shares of Enliven Therapeutics by 4.3% in the 2nd quarter. Invesco Ltd. now owns 21,957 shares of the company’s stock valued at $440,000 after purchasing an additional 913 shares during the last quarter. BNP Paribas Financial Markets grew its position in Enliven Therapeutics by 33.3% in the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after acquiring an additional 930 shares during the last quarter. Quantbot Technologies LP raised its stake in Enliven Therapeutics by 47.1% during the second quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock worth $90,000 after acquiring an additional 1,434 shares in the last quarter. Legal & General Group Plc raised its stake in Enliven Therapeutics by 4.8% during the third quarter. Legal & General Group Plc now owns 33,765 shares of the company’s stock worth $691,000 after acquiring an additional 1,540 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Enliven Therapeutics by 8.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,729 shares of the company’s stock worth $428,000 after acquiring an additional 1,693 shares during the last quarter. Institutional investors own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.